All In Biotech

Drug Trial Radar · NCT01761266

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 954 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

954

Actual

Start

Mar 1, 2013

Primary completion

Nov 13, 2016

Study completion Mar 10, 2021

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • LenvatinibDrug

    12 mg (or 8 mg) once daily (QD) oral dosing.

  • SorafenibDrug

    400 mg twice daily (BID) oral dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization until date of death from any cause (approximately up to 3.8 years)

Locations

186 sites in 21 countries. Site status is shown where the registry gives one.

  • Facility # 1

    Los Angeles, California

  • Facility # 1

    Sacramento, California

  • Facility # 1

    San Francisco, California

  • Facility # 1

    Washington D.C., District of Columbia

  • Facility # 1

    Tampa, Florida

  • Facility # 1

    Duluth, Georgia

  • Facility # 1

    Lawrenceville, Georgia

  • Facility # 1

    Baltimore, Maryland

  • Facility # 1

    Detroit, Michigan

  • Facility # 1

    Kansas City, Missouri

  • Facility # 1

    St Louis, Missouri

  • Facility # 1

    East Orange, New Jersey

  • Facility # 1

    Brooklyn, New York

  • Facility # 1

    Lake Success, New York

  • Facility # 1

    New York, New York

  • Facility # 1

    Charlotte, North Carolina

  • Facility # 1

    Durham, North Carolina

  • Facility # 1

    Portland, Oregon

  • Facility # 1

    Austin, Texas

  • Facility # 1

    Lubbock, Texas

  • Facility # 1

    Seattle, Washington

  • Facility # 1

    Camperdown, New South Wales, Australia

  • Facility # 1

    Wentworthville, New South Wales, Australia

  • Facility # 1

    Woolloongabba, Queensland, Australia

  • Facility # 1

    Fitzroy, Victoria, Australia

  • Facility # 1

    Melbourne, Victoria, Australia

  • Facility # 2

    Melbourne, Victoria, Australia

  • Facility # 1

    Nedlands, Western Australia, Australia

  • Facility # 1

    Brussels, Belgium

  • Facility # 1

    Edegem, Belgium

  • Facility # 1

    Liège, Belgium

  • Facility # 1

    Ottawa, Ontario, Canada

  • Facility # 1

    Hefei, Anhui, China

  • Facility # 1

    Beijing, Beijing Municipality, China

  • Facility # 2

    Beijing, Beijing Municipality, China

  • Facility # 3

    Beijing, Beijing Municipality, China

  • Facility # 1

    Chongqing, Chongqing Municipality, China

  • Facility # 1

    Fuzhou, Fujian, China

  • Facility # 2

    Fuzhou, Fujian, China

  • Facility # 1

    Guangzhou, Guangdong, China

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.